No­var­tis' San­doz splurges on a trio of GSK an­tibi­otics, dou­bling down with a $500M bet on a field strug­gling to com­bat re­sis­tant mi­crobes

Most ma­jor drug­mak­ers over the past few years have fled the an­tibi­otics space, which has been dou­bly hit by re­sis­tant “su­per bugs” and scarce in­no­va­tion. No­var­tis was one of those R&D evac­uees, hit­ting the eject but­ton back in 2018, but on the gener­ic an­tibi­otics front it’s still hang­ing in there and even adding to its port­fo­lio.

San­doz will shell out $350 mil­lion up­front and an ad­di­tion­al $150 mil­lion in down­stream mile­stones for three of GSK’s cephalosporin an­tibi­otics, most no­tably Zin­nat, the Swiss gener­ics mak­er said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.